Cancer Drug Resistance (CDR) is an international peer-reviewed, open access, online journal.
Cancer Drug Resistance is a quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original research. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.
The journal is owned by OAE Publishing Inc.
All articles published by CDR are made freely and permanently accessible online immediately from the date of publication. For further information, please refer to Open Access. Articles are published under a Creative Commons Attribution 4.0 International License (CC BY). The CC BY allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source.
Authors retain the copyright of their works as well as the rights to make certain uses of the works.
For more information about the editorial team, please refer to Editorial Board.
All manuscripts submitted to CDR should adhere to OAE's Editorial Policies.
Please visit Contact Us for details about different queries.